The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Incretin-Based Drugs Market Research Report 2025
Synopsis
The global Incretin-Based Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Incretin-Based Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Incretin-Based Drugs.
Report Scope
The Incretin-Based Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Incretin-Based Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Incretin-Based Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Johnson & Johnson
Merck & Co
AstraZeneca
Novartis
Eli Lilly and Company
Boehringer Ingelheim
Takeda Pharmaceutical Company
Sanofi
Segment by Type
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Segment by Application
Oral Drugs
Injectable Drugs
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Incretin-Based Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Incretin-Based Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Incretin-Based Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Incretin-Based Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Incretin-Based Drugs.
Report Scope
The Incretin-Based Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Incretin-Based Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Incretin-Based Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Johnson & Johnson
Merck & Co
AstraZeneca
Novartis
Eli Lilly and Company
Boehringer Ingelheim
Takeda Pharmaceutical Company
Sanofi
Segment by Type
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Segment by Application
Oral Drugs
Injectable Drugs
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Incretin-Based Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Incretin-Based Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Incretin-Based Drugs Market Overview
1.1 Product Overview and Scope of Incretin-Based Drugs
1.2 Incretin-Based Drugs Segment by Type
1.2.1 Global Incretin-Based Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Glucagon-like peptide-1 receptor (GLP-1) agonists
1.2.3 Dipeptidyl Peptidase-4 (DPP-4) inhibitors
1.3 Incretin-Based Drugs Segment by Application
1.3.1 Global Incretin-Based Drugs Market Value by Application: (2024-2030)
1.3.2 Oral Drugs
1.3.3 Injectable Drugs
1.4 Global Incretin-Based Drugs Market Size Estimates and Forecasts
1.4.1 Global Incretin-Based Drugs Revenue 2019-2030
1.4.2 Global Incretin-Based Drugs Sales 2019-2030
1.4.3 Global Incretin-Based Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Incretin-Based Drugs Market Competition by Manufacturers
2.1 Global Incretin-Based Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Incretin-Based Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Incretin-Based Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Incretin-Based Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Incretin-Based Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Incretin-Based Drugs, Product Type & Application
2.7 Incretin-Based Drugs Market Competitive Situation and Trends
2.7.1 Incretin-Based Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Incretin-Based Drugs Players Market Share by Revenue
2.7.3 Global Incretin-Based Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Incretin-Based Drugs Retrospective Market Scenario by Region
3.1 Global Incretin-Based Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Incretin-Based Drugs Global Incretin-Based Drugs Sales by Region: 2019-2030
3.2.1 Global Incretin-Based Drugs Sales by Region: 2019-2024
3.2.2 Global Incretin-Based Drugs Sales by Region: 2025-2030
3.3 Global Incretin-Based Drugs Global Incretin-Based Drugs Revenue by Region: 2019-2030
3.3.1 Global Incretin-Based Drugs Revenue by Region: 2019-2024
3.3.2 Global Incretin-Based Drugs Revenue by Region: 2025-2030
3.4 North America Incretin-Based Drugs Market Facts & Figures by Country
3.4.1 North America Incretin-Based Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Incretin-Based Drugs Sales by Country (2019-2030)
3.4.3 North America Incretin-Based Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Incretin-Based Drugs Market Facts & Figures by Country
3.5.1 Europe Incretin-Based Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Incretin-Based Drugs Sales by Country (2019-2030)
3.5.3 Europe Incretin-Based Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Incretin-Based Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Incretin-Based Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Incretin-Based Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Incretin-Based Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Incretin-Based Drugs Market Facts & Figures by Country
3.7.1 Latin America Incretin-Based Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Incretin-Based Drugs Sales by Country (2019-2030)
3.7.3 Latin America Incretin-Based Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Incretin-Based Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Incretin-Based Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Incretin-Based Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Incretin-Based Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Incretin-Based Drugs Sales by Type (2019-2030)
4.1.1 Global Incretin-Based Drugs Sales by Type (2019-2024)
4.1.2 Global Incretin-Based Drugs Sales by Type (2025-2030)
4.1.3 Global Incretin-Based Drugs Sales Market Share by Type (2019-2030)
4.2 Global Incretin-Based Drugs Revenue by Type (2019-2030)
4.2.1 Global Incretin-Based Drugs Revenue by Type (2019-2024)
4.2.2 Global Incretin-Based Drugs Revenue by Type (2025-2030)
4.2.3 Global Incretin-Based Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Incretin-Based Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Incretin-Based Drugs Sales by Application (2019-2030)
5.1.1 Global Incretin-Based Drugs Sales by Application (2019-2024)
5.1.2 Global Incretin-Based Drugs Sales by Application (2025-2030)
5.1.3 Global Incretin-Based Drugs Sales Market Share by Application (2019-2030)
5.2 Global Incretin-Based Drugs Revenue by Application (2019-2030)
5.2.1 Global Incretin-Based Drugs Revenue by Application (2019-2024)
5.2.2 Global Incretin-Based Drugs Revenue by Application (2025-2030)
5.2.3 Global Incretin-Based Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Incretin-Based Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline Incretin-Based Drugs Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Incretin-Based Drugs Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Merck & Co
6.3.1 Merck & Co Corporation Information
6.3.2 Merck & Co Description and Business Overview
6.3.3 Merck & Co Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck & Co Incretin-Based Drugs Product Portfolio
6.3.5 Merck & Co Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Corporation Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AstraZeneca Incretin-Based Drugs Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Incretin-Based Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Eli Lilly and Company
6.6.1 Eli Lilly and Company Corporation Information
6.6.2 Eli Lilly and Company Description and Business Overview
6.6.3 Eli Lilly and Company Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly and Company Incretin-Based Drugs Product Portfolio
6.6.5 Eli Lilly and Company Recent Developments/Updates
6.7 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Boehringer Ingelheim Incretin-Based Drugs Product Portfolio
6.7.5 Boehringer Ingelheim Recent Developments/Updates
6.8 Takeda Pharmaceutical Company
6.8.1 Takeda Pharmaceutical Company Corporation Information
6.8.2 Takeda Pharmaceutical Company Description and Business Overview
6.8.3 Takeda Pharmaceutical Company Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Pharmaceutical Company Incretin-Based Drugs Product Portfolio
6.8.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Corporation Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Incretin-Based Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sanofi Incretin-Based Drugs Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Incretin-Based Drugs Industry Chain Analysis
7.2 Incretin-Based Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Incretin-Based Drugs Production Mode & Process
7.4 Incretin-Based Drugs Sales and Marketing
7.4.1 Incretin-Based Drugs Sales Channels
7.4.2 Incretin-Based Drugs Distributors
7.5 Incretin-Based Drugs Customers
8 Incretin-Based Drugs Market Dynamics
8.1 Incretin-Based Drugs Industry Trends
8.2 Incretin-Based Drugs Market Drivers
8.3 Incretin-Based Drugs Market Challenges
8.4 Incretin-Based Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
